Exagen (XGN) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings or view top-rated stocks.

4 brokers have issued 1-year price objectives for Exagen's shares. Their XGN share price forecasts range from $5.00 to $7.00. On average, they anticipate the company's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price.
View analysts price targets for XGN or view top-rated stocks among Wall Street analysts.

Exagen's stock was trading at $2.40 at the beginning of 2023. Since then, XGN stock has increased by 31.3% and is now trading at $3.15.
View the best growth stocks for 2023 here.

Exagen saw a decline in short interest in May. As of May 15th, there was short interest totaling 7,000 shares, a decline of 54.5% from the April 30th total of 15,400 shares. Based on an average trading volume of 20,100 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the company's stock are sold short.
View Exagen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XGN earnings forecast.

Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings data on Monday, March, 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.13. The firm had revenue of $12.84 million for the quarter, compared to analyst estimates of $8.63 million. Exagen had a negative net margin of 90.98% and a negative trailing twelve-month return on equity of 79.22%.

Exagen updated its first quarter 2023 earnings guidance on Tuesday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $9.20 million-$9.70 million, compared to the consensus revenue estimate of $9.33 million.

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.

(XGN) raised $50 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Exagen trades on the NASDAQ under the ticker symbol "XGN."

Exagen's stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (8.26%), Stonepine Capital Management LLC (6.15%), Cowen AND Company LLC (5.60%), Perkins Capital Management Inc. (1.54%), UBS Group AG (0.78%) and First Bank & Trust (0.10%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson.
View institutional ownership trends.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XGN stock can currently be purchased for approximately $3.15.

Exagen (NASDAQ:XGN) has a market capitalization of $53.08 million and generates $45.56 million in revenue each year. The company earns $-47,390,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.

The company employs 219 workers across the globe.

Exagen's mailing address is 1261 Liberty Way Suite C, VISTA CA, 92081. The official website for the company is www.exagen.com. The company can be reached via phone at 760-560-1501 or via email at ir@exagen.com.